UT researchers were the first to develop engineered human enzymes for cancer therapy. Deletion of the enzyme MTAP in tumors results in the accumulation and secretion of MTA, a very potent immunosuppressive molecule. UT researchers are currently developing an optimized MTA degrading drug that has the needed pharmacological properties for late/stage preclinical/clinical administration.
